Relay Therapeutics (RLAY) Consolidated Net Income (2019 - 2026)

Relay Therapeutics (RLAY) has reported Consolidated Net Income for 8 consecutive years, with -$79.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 1.49% year-over-year to -$79.1 million; the TTM figure through Mar 2026 stood at -$262.4 million (up 64.77% YoY), while the FY2025 annual figure was -$756.2 million, up 1.75% from the prior year.
• Consolidated Net Income slipped to -$79.1 million in Q1 2026 per RLAY's latest filing, from -$35.1 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$35.1 million in Q4 2025 and bottomed at -$484.9 million in Q4 2024.
• Historically, Consolidated Net Income has averaged -$106.9 million across 5 years, with a median of -$82.7 million in 2024.
• Annual changes were most pronounced in 2024 — Consolidated Net Income tumbled 349.31% — and 2025, when it jumped 92.76%.
• Relay Therapeutics' Consolidated Net Income stood at -$75.1 million in 2022, then plunged by 43.77% to -$107.9 million in 2023, then tumbled by 349.31% to -$484.9 million in 2024, then surged by 92.76% to -$35.1 million in 2025, then sank by 125.53% to -$79.1 million in 2026.
• Business Quant data shows RLAY's Consolidated Net Income at -$79.1 million in Q1 2026, -$35.1 million in Q4 2025, and -$74.2 million in Q3 2025.